Bosutinib In Subjects With Renal Impairment

• Renal Disease, End-Stage
• Renal Insufficiency, Chronic
• Renal Insufficiency, Acute

• Drug: Bosutinib
  
  Single dose of 200 mg of bosutinib in subjects with normal renal function
• Drug: Bosutinib
  
  Single dose of 200 mg of bosutinib in subjects with mild renal impairment
• Drug: Bosutinib
  
  Single dose of 200 mg of bosutinib in subjects with moderate renal impairment
• Drug: Bosutinib
  
  Single dose of 200 mg of bosutinib in subjects with severe renal impairment

• Experimental: Healthy Volunteers
  
  Intervention: Drug: Bosutinib
• Experimental: Mild Renal Impairment
  
  Intervention: Drug: Bosutinib
• Experimental: Moderate Renal Impairment
  
  Intervention: Drug: Bosutinib
• Experimental: Severe Renal Impairment
  
  Intervention: Drug: Bosutinib

Inclusion Criteria:

• Males and females, aged 18 to 65.
• Adequate hepatic function.
• Documented creatinine clearance by Cockroft-Gault formula indicative of the respective level of renal impairment: Severe renal impairment (CrCl <30 mL/min/1.73m2), moderate renal impairment (30 ? CrCl ?50 mL/min/1.73m2), mild renal impairment (50 < CrCl?80 mL/min/1.73m2) and normal renal function (CrCl >80 mL/min/1.73m2).

Exclusion Criteria:

• Use of any investigational drug or biologic within 4 weeks prior to the screening visit of during the screening period.
• Ongoing treatment with Digoxin or strong CYP3A4 inhibitors or inducers.
• Uncontrolled hypertension (for renally impaired subjects only).